These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33471125)

  • 1. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation.
    Lee SR; Choi EK; Park SH; Jung JH; Han KD; Oh S; Lip GYH
    Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):415-423. PubMed ID: 33471125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes.
    Campbell AM; Pae E; Lee E; Jacisin T; Price A; DeAngelo J
    Ann Pharmacother; 2024 Jun; 58(6):572-580. PubMed ID: 37712551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    van den Dries CJ; Pajouheshnia R; van den Ham HA; Souverein P; Moons KGM; Hoes AW; Geersing GJ; van Doorn S
    Br J Clin Pharmacol; 2023 Feb; 89(2):751-761. PubMed ID: 36102068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Apixaban Prescribing Patterns for Nonvalvular Atrial Fibrillation in Hospitalized Patients.
    Gibson CM; Smith CB; Davis S; Scalese MJ
    Ann Pharmacother; 2018 Jan; 52(1):54-59. PubMed ID: 28799408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA
    Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
    Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
    Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.
    Li XS; Deitelzweig S; Keshishian A; Hamilton M; Horblyuk R; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Lip GYH
    Thromb Haemost; 2017 Jun; 117(6):1072-1082. PubMed ID: 28300870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
    J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter.
    Ashraf H; Agasthi P; Shanbhag A; Mehta RA; Rattanawong P; Allam M; Pujari SH; Mookadam F; Freeman WK; Srivathsan K; Sorajja D; Shen WK; Noseworthy PA; Yang EH; Masry HZE; Yao X; Mulpuru SK; Beohar N; Holmes DR; Arsanjani R
    Am J Med; 2021 Jun; 134(6):788-796. PubMed ID: 33444586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.
    Coleman CI; Peacock WF; Antz M
    Heart Lung Circ; 2018 Mar; 27(3):390-393. PubMed ID: 28528780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial apixaban dosing in patients with atrial fibrillation.
    Buchholz A; Ueberham L; Gorczynska K; Dinov B; Hilbert S; Dagres N; Husser D; Hindricks G; Bollmann A
    Clin Cardiol; 2018 May; 41(5):671-676. PubMed ID: 29542830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.
    Alexander JH; Andersson U; Lopes RD; Hijazi Z; Hohnloser SH; Ezekowitz JA; Halvorsen S; Hanna M; Commerford P; Ruzyllo W; Huber K; Al-Khatib SM; Granger CB; Wallentin L;
    JAMA Cardiol; 2016 Sep; 1(6):673-81. PubMed ID: 27463942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
    Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.